We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
326
Palvella Therapeutics
PVLA
$2.05B
– –
-16,200
Closed -$1.81M
NVRO
327
CALL
DELISTED
NEVRO CORP.
NVRO
– –
-165
Closed -$1.2M
LUMO
328
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-6,254
Closed -$893K
ALPN
329
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-10,001
Closed -$90K
SIEN
330
DELISTED
Sientra, Inc.
SIEN
– –
-7,097
Closed -$605K
SIEN
331
PUT
DELISTED
Sientra, Inc.
SIEN
– –
-241
Closed -$2.06M
DMK
332
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-2
Closed -$42K
PRTK
333
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-110,000
Closed -$1.73M
ISEE
334
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-883
Closed -$426K
BIOC
335
DELISTED
Biocept, Inc.
BIOC
– –
-46
Closed -$319K
VYNT
336
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
– –
-480
Closed -$97K
CLVS
337
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-420
Closed -$1.87M
TMBR
338
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-47
Closed -$265K
ATHX
339
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-1,731
Closed -$66K
ENDP
340
DELISTED
Endo International plc
ENDP
– –
-126,139
Closed -$2.08M
ENDP
341
PUT
DELISTED
Endo International plc
ENDP
– –
-1,323
Closed -$2.18M
ZSAN
342
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-148
Closed -$81K
ADXS
343
DELISTED
Advaxis Inc
ADXS
– –
-696
Closed -$90.4K
FLXN
344
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-10,914
Closed -$223K
VKTXW
345
DELISTED
Viking Therapeutics, Inc.
VKTXW
– –
-86,349
Closed -$39K
IMMU
346
DELISTED
Immunomedics Inc
IMMU
– –
-50,000
Closed -$253K
SCON
347
DELISTED
Superconductor Technologies Inc.
SCON
– –
-4,347
Closed -$535K
EYEGW
348
DELISTED
Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
– –
-20,604
Closed -$6K
BLPH
349
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
– –
-52,657
Closed -$414K
MDCO
350
DELISTED
Medicines Co
MDCO
– –
-112,392
Closed -$5.13M
11 12 13
14
15

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.